GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Unity Biotechnology
Unity Biotechnology is a biotech company focused on treating age-related diseases. Its stock price reflects both the great potential of this field and past clinical trial failures.
Share prices of companies in the market segment - Dna
Unity Biotechnology is a biotech company developing drugs to treat age-related diseases by eliminating senescent cells. We've classified it as a "DNA" company. The chart below shows how investors view the anti-aging sector.
Broad Market Index - GURU.Markets
Unity Biotechnology is a biotech company developing drugs to treat age-related diseases by eliminating senescent cells. As a pioneer, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Unity's performance to assess the state of the sector.
Change in the price of a company, segment, and market as a whole per day
UBX - Daily change in the company's share price Unity Biotechnology
Unity Biotechnology, Inc.'s daily share price fluctuations reflect the high volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its age-related drug candidates.
Daily change in the price of a set of shares in a market segment - Dna
Unity Biotechnology develops anti-aging drugs (senolytics) aimed at treating age-related diseases. This is a cutting-edge and highly speculative area of biotech. The chart below illustrates the high volatility typical of this sector, reflecting the risks and potential of UBX.
Daily change in the price of a broad market stock, index - GURU.Markets
Unity Biotechnology is a pioneer in the development of anti-aging drugs (senolytics). The company's shares are a bet on a scientific revolution in medicine. Their high volatility, dependent on research results, is part of the dynamic nature of the innovation sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Unity Biotechnology
Unity Biotechnology's year-over-year performance is a story of its drug development for age-related eye diseases. Its 12-month market cap is entirely dependent on clinical trial data. The success of its lead candidate, which targets senescent cells, could be a breakthrough in ophthalmology.
Annual dynamics of market capitalization of the market segment - Dna
Unity, a biotech company, develops drugs to treat aging-related diseases. Its performance is completely separate from the sector and depends on news about clinical trials. Its stock price will reflect investors' speculative belief in the potential of its innovative approach to medicine.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Unity Biotechnology is one of the most ambitious biotech companies, betting on the fight against aging. Its performance is completely unrelated to the market and is a pure reflection of investors' faith in its scientific concept. Success will mean a revolution in medicine and explosive share price growth.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Unity Biotechnology
Unity is a biotech company developing anti-aging drugs. Its monthly growth is entirely dependent on the results of its clinical trials. Data from its programs for the treatment of eye diseases and neurological disorders is the main driver.
Monthly dynamics of market capitalization of the market segment - Dna
Unity Biotechnology is a biotech company developing senolytics (drugs that selectively destroy senescent cells) to treat diseases of aging. The graph below shows the dynamics of the biotech sector, where anti-aging is one of the most ambitious goals.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Unity Biotechnology is a biotech company developing anti-aging drugs. This is a cutting-edge, yet risky, field of science. The company's shares are driven by news of clinical trials, and their performance is completely disconnected from overall market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Unity Biotechnology
Unity Biotechnology, a company developing drugs against diseases of aging, is experiencing high volatility. Weekly stock performance is driven by news about preclinical and clinical trials, reflecting the high risks and enormous potential for breakthroughs in gerontology.
Weekly dynamics of market capitalization of the market segment - Dna
Unity Biotechnology and the entire anti-aging biotech sector are riding a wave of news about breakthroughs in this field. Investor sentiment around the entire concept is creating extreme volatility for everyone. The chart will reveal whether the company is leading the hype.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Unity Biotechnology is a biotech company focused on anti-aging. Its shares exist in a world of their own, driven by research data. The chart clearly demonstrates that UBX's performance is largely uncorrelated with the market, driven by its unique development news.
Market capitalization of the company, segment and market as a whole
UBX - Market capitalization of the company Unity Biotechnology
The Unity Biotechnology chart is a financial map of the fight against aging at the cellular level. The company's market cap reflects the hopes for its drugs aimed at destroying senescent cells. Its volatility mirrors the riskiness of clinical trials, where any result could either advance a revolution in anti-aging medicine or set it back.
UBX - Share of the company's market capitalization Unity Biotechnology within the market segment - Dna
Unity Biotechnology is at the forefront of the fight against aging. The company's market capitalization in the biotech sector reflects investors' bet on its scientific approach. A small but growing shareholder base could signal a breakthrough in drug development that could change the understanding of age-related diseases.
Market capitalization of the market segment - Dna
Unity Biotechnology is a pioneer in anti-aging drug development. The chart below shows the overall market capitalization of the entire biotech sector. Its dynamics reflect investors' belief that science can find ways to slow or reverse the aging process.
Market capitalization of all companies included in a broad market index - GURU.Markets
Unity Biotechnology is a company developing anti-aging drugs at the cellular level. Its market capitalization is a financial bet on one of the most ambitious ideas in medicine. Its volatile valuation, compared to the market, reflects the enormous potential and high risks of the anti-aging campaign.
Book value capitalization of the company, segment and market as a whole
UBX - Book value capitalization of the company Unity Biotechnology
Unity Biotechnology's book value represents its R&D capital. The chart below visualizes its financial runway. The decline reflects the company's consistent spending on clinical trials of anti-aging drugs. This is the cost of research.
UBX - Share of the company's book capitalization Unity Biotechnology within the market segment - Dna
Unity Biotechnology is a biotech company developing anti-aging drugs. Its main asset is its scientific platform. The share of tangible assets will be low, reflecting its focus on R&D, where the primary focus is on laboratories rather than large-scale manufacturing facilities.
Market segment balance sheet capitalization - Dna
Below you can see the overall book value of the biotech sector. Compared to this, Unity Biotechnology, which develops anti-aging drugs, looks like a "lightweight." Its value lies in its scientific platform and patents, not in its large manufacturing facilities, which is typical for a company focused on R&D.
Book value of all companies included in the broad market index - GURU.Markets
Unity Biotechnology is a company developing drugs against diseases of aging. Its assets are not factories, but patents and clinical trial data. The company's balance sheet is the value of its scientific approach to "repairing" biological mechanisms. Amidst the entire material economy, Unity is trying to extend the lifespan of its most important component—humans.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Unity Biotechnology
Unity Biotechnology's balance sheet represents its cash and patents. Its market capitalization represents the bet that its anti-aging drugs will one day work. The MvsBCap_Co chart shows how the market values this "dream of eternal youth" relative to the company's actual cash holdings.
Market to book capitalization ratio in a market segment - Dna
Unity Biotechnology develops drugs to combat aging at the cellular level. Its value lies in its cutting-edge science. The chart shows a high speculative valuation of its potential to slow or reverse age-related diseases, which is many times greater than the value of its tangible assets.
Market to book capitalization ratio for the market as a whole
Unity Biotechnology is working at the forefront of science, developing anti-aging drugs. It's a classic example of biotech, where market capitalization is a bet on a future breakthrough. The chart shows a huge gap between the current book value (laboratory) and the market valuation, reflecting investor hopes for the success of revolutionary drugs.
Debts of the company, segment and market as a whole
UBX - Company debts Unity Biotechnology
Unity Biotechnology, a company developing anti-aging drugs, uses debt to finance its cutting-edge research. This chart shows how the company raises capital to conduct preclinical and clinical trials. In this disruptive but long-term field of science, debt is a vital resource for testing bold hypotheses.
Market segment debts - Dna
Unity Biotechnology is a biotech company focused on developing drugs to combat aging-related diseases. This is a cutting-edge, yet risky, field of science. This chart shows how the clinical-stage company funds its expensive research, striving to achieve breakthroughs in longevity medicine.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Unity Biotechnology
Unity Biotechnology is a company working on anti-aging drugs. It's a cutting-edge, yet extremely risky, field of science. This chart shows how dependent its existence is on external funding. It directly reflects the enormous stake it places on scientific breakthroughs, where debt fuels research that could either fail or change the world.
Market segment debt to market segment book capitalization - Dna
Unity Biotechnology is a biotech company developing anti-aging drugs (senolytics). This is a cutting-edge, but very expensive, area of research. The chart shows how the company's debt load for R&D funding compares to the market capitalization and risks of the overall biotech sector.
Debt to book value of all companies in the market
Unity Biotechnology (UBX) is a biotech company developing drugs to combat diseases of aging. Currently in clinical trials, it is primarily funded through equity. This chart shows the overall market leverage, clearly demonstrating the contrast between the financial models of innovative biotech companies and mature corporations.
P/E of the company, segment and market as a whole
P/E - Unity Biotechnology
This chart for Unity Biotechnology, a company developing drugs for age-related diseases, is a measure of hope. There's no P/E ratio here, as the company is focused on research. Its valuation is based on the potential of its scientific approach to "cleansing" the body of senescent cells. Its performance depends on news about clinical trials.
P/E of the market segment - Dna
This chart shows the average P/E ratio for biotech companies. For Unity Biotechnology, which is focused on anti-aging, it serves as a backdrop. It reflects the general level of investor faith in breakthrough but risky scientific concepts, providing context for Unity's valuation, which is a bet on its unique platform.
P/E of the market as a whole
Unity Biotechnology develops anti-aging drugs at the cellular level, targeting the elimination of senescent cells. This is a cutting-edge, yet high-risk, field of science. This chart shows the overall risk appetite of investors. It helps us understand whether Unity is receiving funding due to general market optimism and faith in breakthrough technologies, or whether its valuation is driven solely by scientific data.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Unity Biotechnology
Unity Biotechnology is a biotech company focused on developing drugs against diseases of aging. For a clinical-stage company, this chart reflects not current revenues but analysts' belief in a scientific breakthrough. It shows the potential future profit the market is pricing in, anticipating successful research results.
%20P%2FE%20Unity%20Biotechnology&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Unity-Biotechnology&v=1772513445543 "Chart of the company's future (projected) P/E Unity Biotechnology")
Future (projected) P/E of the market segment - Dna
Unity Biotechnology develops drugs to combat diseases of aging by eliminating senescent cells. This chart shows average expectations for the biotech sector. UBX's position may indicate the extent to which investors believe in its revolutionary approach to medicine and the potential of its scientific developments, despite the high risks.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772513445556 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Unity Biotechnology is developing anti-aging drugs. This is a cutting-edge and risky field of science. General market optimism, reflected in this chart, is vital for such companies, as it drives investor appetite for funding long-term, breakthrough research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513445567 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Unity Biotechnology
Unity Biotechnology is a biopharmaceutical company developing drugs to combat aging-related diseases by eliminating senescent cells. This graph illustrates the path to a "cure for aging." It shows significant investment in research, with future profits directly dependent on the success of their drugs in clinical trials.
Profit of companies in the market segment - Dna
Unity Biotechnology is a company developing drugs to combat aging-related diseases by targeting senescent cells. The profitability of this cutting-edge sector, as the chart shows, reflects hopes for a revolution in gerontology. UBX's success depends on proving that aging can be treated as a disease, which would open up a huge market.
Overall market profit
Unity Biotechnology, which is working on anti-aging drugs, is aiming to solve a fundamental biological problem. Its success depends on scientific breakthroughs, not the economic cycle shown by this chart. However, overall market conditions are critical to attracting the massive investment required for lengthy and costly clinical trials.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Unity Biotechnology
Unity Biotechnology is a biopharmaceutical company focused on combating aging at the cellular level. This chart shows analyst expectations, which are essentially a bet on the success of its scientific developments. The profit forecast reflects the market's confidence that its drugs will pass clinical trials and reach commercialization.
%20profit%20of%20the%20company%20Unity%20Biotechnology&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Unity-Biotechnology&v=1772513445602 "Graph of future (projected) profit of the company Unity Biotechnology")
Future (predicted) profit of companies in the market segment - Dna
Unity Biotechnology is developing treatments for diseases of aging by clearing senescent cells from the body. This is cutting-edge science with enormous potential. This chart shows profit forecasts for the biotech sector, reflecting the overall optimism or skepticism of investors regarding breakthrough but risky scientific platforms.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772513445611 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
Unity Biotechnology develops drugs to combat aging at the cellular level. Like most biotech companies, its value depends on scientific breakthroughs. The overall economic outlook is important for the investment climate. During periods of optimism, reflected in a positive outlook, investors are more willing to invest in risky but promising technologies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513445619 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Unity Biotechnology
Unity Biotechnology develops drugs aimed at combating diseases of aging by destroying senescent cells. At the clinical stage, the company has almost no revenue. The chart reflects investors' pure faith in its scientific platform. The valuation is based on the potential of future breakthrough drugs, not current sales.
P/S market segment - Dna
Unity Biotechnology develops drugs to treat age-related diseases by eliminating senescent cells. The chart shows the average revenue estimate in the biotech sector. It allows us to estimate the premium investors are pricing the company for its innovative approach to fighting aging compared to the industry average.
P/S of the market as a whole
Unity Biotechnology is developing drugs to combat aging at the cellular level, targeting age-related diseases. The company's revenue is currently minimal, and its value is determined by its scientific potential. The chart showing the average market revenue estimate emphasizes that investors are buying not current sales, but the hope for a revolution in medicine.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Unity Biotechnology
Unity Biotechnology develops drugs to combat diseases of aging. For such an early-stage company, its valuation is based on expectations. The chart reflects this expectation, correlating the current valuation with the potentially enormous future revenues that could be generated if its revolutionary therapies are successful.
%20P%2FS%20Unity%20Biotechnology&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Unity-Biotechnology&v=1772513445683 "The graph of the company's future (projected) P/S Unity Biotechnology")
Future (projected) P/S of the market segment - Dna
Unity Biotechnology develops drugs to treat age-related diseases by eliminating senescent cells. This chart illustrates average future sales expectations for biotech companies. It helps investors understand how highly the market values Unity's scientific approach and the potential of its developments compared to other innovators.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772513445711 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
Unity Biotechnology is developing drugs against diseases of aging. This is a breakthrough field where value is created by scientific discoveries. This graph of overall revenue expectations is irrelevant. UBX's entire value lies in the success of its scientific platform. The approval of a single drug could change its fate, regardless of the state of the economy.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513445714 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Unity Biotechnology
Unity Biotechnology is a biopharmaceutical company developing drugs to combat diseases of aging. Being in clinical trials, the company typically does not have stable sales revenue. The revenue in this graph likely represents payments from strategic partners who support its innovative developments.
Sales of companies in the market segment - Dna
Unity Biotechnology is a biotech company developing drugs to combat diseases associated with aging. Their approach is based on eliminating senescent cells, which accumulate in the body with age. This chart shows the total revenue in the sector, reflecting the progress and commercial potential in the field of "anti-aging drugs."
Overall market sales
Unity Biotechnology is a biopharmaceutical company developing drugs to treat age-related diseases. Its market capitalization depends on the results of clinical trials. The overall economic situation, reflected in this chart, influences investor willingness to finance long-term and risky projects in the longevity field.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Unity Biotechnology
Unity Biotechnology is a biotech company focused on developing treatments for diseases of aging by eliminating senescent cells. Its future depends entirely on the success of clinical trials. This chart reflects speculative market expectations regarding a potential breakthrough in anti-aging medicine.
%20sales%20of%20the%20company%20Unity%20Biotechnology&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Unity-Biotechnology&v=1772513446068 "Schedule of future (projected) sales of the company Unity Biotechnology")
Future (projected) sales of companies in the market segment - Dna
Unity Biotechnology is a biotech company focused on developing drugs to combat diseases of aging by eliminating senescent cells. This is at the cutting edge of science. The data in the graph reflects forecasts for the entire biopharmaceutical industry. If Unity's technology is successful, its potential is enormous.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772513446071 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
Unity Biotechnology develops drugs to combat aging at the cellular level. For such a cutting-edge company, the overall investment climate is important. This chart, reflecting economic confidence, influences investor willingness to invest in the long-term, high-risk, but potentially revolutionary medical research being conducted by UBX.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513446080 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Unity Biotechnology
Unity Biotechnology is a biotech company focused on combating diseases of aging. While in clinical trials, it incurs significant research expenses. This chart illustrates the financial side of innovation: current expenses are an investment in the development of breakthrough drugs that could generate significant profits in the future.
Market segment marginality - Dna
Unity Biotechnology is a biopharmaceutical company developing drugs to treat aging-related diseases. This chart shows the average revenue in the pharmaceutical industry. As a clinical-stage company, its future ability to exceed this figure depends entirely on the success of its innovative developments and their commercialization.
Market marginality as a whole
Unity Biotechnology is a biotech company focused on developing drugs for diseases of aging. It's in early-stage research, and its financial performance is driven by burning through investments for the sake of future discoveries. This total profit chart highlights the stark difference between current corporate profitability and long-term bets on medical breakthroughs.
Employees in the company, segment and market as a whole
Number of employees in the company Unity Biotechnology
Unity Biotechnology is a company focused on combating aging at the cellular level. At the forefront of science, its greatest asset is its intellectual capital. This chart shows the size of its team of scientists and researchers who are the driving force behind the development of a new class of drugs to treat age-related diseases.
Share of the company's employees Unity Biotechnology within the market segment - Dna
Unity Biotechnology is working at the forefront of science, developing treatments for diseases of aging. In such a breakthrough field, it's not the size of the team that matters, but its quality. This chart shows the percentage of unique scientists specializing in cellular aging that the company has. This allows us to assess its scientific clout not in monetary terms, but in intellectual capital.
Number of employees in the market segment - Dna
Unity Biotechnology is a biotech company developing drugs to treat aging-related diseases. The growth of its research team, visible in this chart, directly correlates with progress in clinical trials. This increase in staff indicates that its innovative anti-aging approaches are advancing through the development stages.
Number of employees in the market as a whole
Unity Biotechnology is challenging aging by developing drugs to eliminate senescent cells. This chart illustrates the company's R&D journey. Its small but growing team of scientists and researchers is its greatest asset. The team's expansion is a direct indicator of progress in clinical trials and investors' faith in its breakthrough science.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Unity Biotechnology (UBX)
Unity Biotechnology is a biopharmaceutical company focused on treating age-related diseases. For companies like these, the primary assets at the research stage are not factories or staff, but patents and scientific research. This metric reflects the "concentration" of intellectual property: market capitalization is based on future expectations from research conducted by a small team of scientists.
%20of%20the%20company%20Unity%20Biotechnology%20(UBX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Unity-Biotechnology-UBX&v=1772513446193 "Chart of market capitalization per employee (in thousands of dollars) of the company Unity Biotechnology (UBX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Unity Biotechnology is a company developing anti-aging drugs at the cellular level. Its market capitalization is based on its potential for breakthrough scientific research, not its manufacturing capacity. This chart shows the company's high market valuation of intellectual capital per scientist.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772513446216 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Unity Biotechnology is a biopharmaceutical company developing drugs to combat diseases of aging. This chart illustrates the company's assessment of scientific potential. For Unity, its high market capitalization per employee reflects not current revenue but rather investors' faith in the breakthrough technology being developed by a small team of scientists.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513446237 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Unity Biotechnology (UBX)
Unity Biotechnology is a clinical-stage biotech company developing therapeutics for diseases of aging (senolytics). The company has no commercial profit. This chart shows the net loss (R&D costs) per scientist working on a future breakthrough in aging treatment.
%20Chart%20Unity%20Biotechnology%20(UBX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Unity-Biotechnology-UBX&v=1772513446252 "Company Profit Per Employee (in thousands of dollars) Chart Unity Biotechnology (UBX)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Unity Biotechnology is a biotech company developing anti-aging drugs (senolytics) aimed at treating age-related diseases. This chart shows the loss per employee during the R&D phase. It serves as a benchmark for assessing how intensively the company is investing in its scientists to validate this breakthrough, yet risky, scientific concept compared to other biotech companies.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772513446274 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Unity Biotechnology is a clinical-stage biotech focused on treating diseases of aging (senolytics). The company is in the R&D phase, has no approved products, and therefore is not profitable. This graph shows a negative value—the investment (loss) per scientist working on breakthrough but not yet commercialized technologies.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513446277 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Unity Biotechnology (UBX)
Unity Biotechnology is developing anti-aging drugs. For a research-stage biopharmaceutical company, this chart highlights key monetization points. Increased revenue per employee typically reflects advance payments from partners, confirming the value of its scientific platform.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Unity-Biotechnology-UBX&v=1772513446286 "Sales chart per company employee Unity Biotechnology (UBX)")
Sales per employee in the market segment - Dna
Unity Biotechnology (UBX) is a clinical-stage biotech developing anti-aging therapies (senolytics). The company has no approved products and, therefore, no commercial revenue. This graph doesn't reflect their value. Staff productivity here would be zero, as the entire staff is focused on R&D, not sales.
Sales per employee for the market as a whole
Unity Biotechnology is a cutting-edge biotech company focused on aging at the cellular level. At the R&D stage, this indicator is expectedly low. The company is investing in highly qualified scientists even before it has a commercial product on the market. This graph is an indicator of the future: it will show an explosive increase in efficacy if clinical trials are successful.
Short shares by company, segment and market as a whole
Shares shorted by company Unity Biotechnology (UBX)
Unity Biotechnology (UBX) is betting on anti-aging. They're developing "senolytics"—drugs that target old, dysfunctional cells to treat age-related diseases (like eye disease). This statistic reflects a bearish bet. Skeptics believe this breakthrough won't prove effective in clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Unity-Biotechnology-UBX&v=1772513446297 "Short Shares Chart for the Company Unity Biotechnology (UBX)")
Shares shorted by market segment - Dna
Unity Biotechnology is a biopharmaceutical company focused on developing drugs against aging-related diseases (senolytics). This is a risky but disruptive field. This indicator reflects the overall bearish sentiment across the biotech sector. High values on the chart indicate that investors generally do not believe in the success of risky developments or anticipate funding problems in the industry, which is important for UDX.
Shares shorted by the overall market
Unity Biotechnology is working in the futuristic field of "anti-aging." This is fundamental science that requires massive investment. This chart reflects a common fear. When investors are pessimistic, they're unwilling to bet on "eternal youth." They see UBX as a money-burner and sell off shares, fearing the company won't live to see a breakthrough.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Unity Biotechnology (UBX)
Unity Biotechnology (UBX) is a biotech company developing senolytics—drugs that eliminate senescent cells, which is believed to treat age-related diseases. This chart measures the rate of price change. It shows when enthusiasm (above 70) for the "anti-aging drug" peaks, or disillusionment (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Unity-Biotechnology-UBX&v=1772513446369 "RSI 14 indicator chart for the company's stock Unity Biotechnology (UBX)")
RSI 14 Market Segment - Dna
Unity Biotech is a "biotech" company that fights *aging*. Their specialty is *senolytics*, drugs that *kill* "senescent" cells (for the treatment of *eye diseases*, *arthritis*). The "Dna" sector (biotech/anti-aging) thrives on hype. RSI_14_Seg shows the "temperature" of this entire segment. It helps us understand: is UBX's growth due to their R&D, or is *the entire* biotech sector "overheated"?
RSI 14 for the overall market
Unity Biotechnology (UBX) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast UBX (Unity Biotechnology)
Unity Biotechnology is a biotech company focused on senolytics—drugs that clear the body of senescent cells to treat age-related diseases. This chart shows the analysts' average 12-month forecast, representing their collective speculative bet on this R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-UBX-Unity-Biotechnology&v=1772513446435 "A chart showing analyst consensus forecasts for the expected stock price. UBX (Unity Biotechnology)")
The difference between the consensus estimate and the actual stock price UBX (Unity Biotechnology)
Unity (UBX) is an anti-aging biotech. The company develops senolytics—drugs that kill senescent cells—for the treatment of eye and neurological diseases. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their faith in this breakthrough R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-UBX-Unity-Biotechnology&v=1772513446463 "A chart showing the difference between the consensus forecast and the actual stock price. UBX (Unity Biotechnology)")
Analyst consensus forecast for stock prices by market segment - Dna
Unity Biotechnology (UBX) is a biotech company attacking "aging." It develops "senolytics"—drugs that "kill" old (senescent) cells—to treat age-related diseases. This chart shows general expectations for the DNA technology sector. It reflects whether experts believe a breakthrough in "anti-aging drugs" is possible.
Analysts' consensus forecast for the overall market share price
Unity Biotechnology (UBX) is a "hunter" for old age. It's a biotech company developing "senolytics"—drugs that "kill" old, decrepit cells—to treat diseases of aging (like blindness). This chart shows the overall risk appetite. It reflects the market's willingness to fund the most ambitious, "sci-fi" R&D projects.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Unity Biotechnology
Unity Biotechnology is a biotech company focused on developing drugs that target cellular senescence (senolytics) for the treatment of age-related diseases (such as eye disease). This is a cutting-edge scientific concept. This chart is a comprehensive barometer reflecting market perception of this innovative, yet high-risk, scientific hypothesis and clinical trial data.
AKIMA Market Segment Index - Dna
Unity Biotechnology (UBX) is DNA and anti-aging. It's a biotech company that develops drugs (senolytics) to destroy old, toxic cells (senescent cells) to treat age-related diseases. This chart compares their composite index to the sector average.
The AKIM Index for the overall market
Unity Biotechnology is a biotech company developing senolytics—drugs that destroy senescent cells—for the treatment of eye diseases (DME). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this scientific story of extending "healthy" lifespan compares to overall economic trends.
